4893.T stock down 16.02% intraday on heavy volume: watch JPY 140.72 support

We logged a sharp intraday drop in 4893.T stock after shares slid 16.02% to JPY 152.00 on very heavy volume of 2,851,100.00 shares on the JPX today, 20 Mar 2026. The move pushed the stock below its 50-day average of JPY 154.20 and triggered technical selling. We break down the drivers, key ratios, Meyka AI grading, and short-term price targets to help traders and investors assess risk.

Intraday market move for 4893.T stock

Noile-Immune Biotech Inc. (4893.T) on the JPX fell from an open of JPY 177.00 to close near JPY 152.00 intraday, a JPY -29.00 change. Volume surged to 2,851,100.00, versus an average volume of 676,056.00, giving a relative volume of 4.22 and confirming this as a top-losers intraday event.

One clear fact: the sell-off was broad and fast, with the day low at JPY 150.00 and day high at JPY 188.00, placing immediate support at the day low and the 50-day average at JPY 154.20.

Drivers behind the decline and sector context for 4893.T stock

There is no single public headline tied to today’s move; trading looks driven by profit-taking and weak biotech sentiment. Noile-Immune (4893.T) is in the Healthcare sector, Biotechnology industry, where investors price high R&D spend and binary clinical outcomes. The company reports R&D/revenue 74.18% and negative EPS of -16.00, which amplifies volatility.

Compared with the Healthcare sector average PE of 23.41, 4893.T shows a negative PE and higher short-term risk. The stock’s large cash per share (JPY 90.49) and book value per share (JPY 90.80) provide a balance to the downside, but earnings remain deeply negative.

Technical snapshot and trading levels for 4893.T stock

Short-term indicators show mixed momentum: RSI 45.65, MACD histogram 0.81, and ADX 32.65 indicating a strong trend. Bollinger Bands middle sits at JPY 163.35 and lower band at JPY 133.68, framing near-term resistance and support.

Key levels: intraday support at JPY 150.00, immediate resistance at JPY 163.35, year low JPY 120.00 and year high JPY 217.00. Traders should note the 50-day average JPY 154.20 and 200-day average JPY 164.12 as reference points for mean-reversion or continued weakness.

Meyka AI rates 4893.T with a score out of 100 and valuation note

Meyka AI rates 4893.T with a score of 64.82 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Valuation metrics show a negative PE and a price-to-book ratio of 1.67, enterprise value JPY 2,663,528,280.00, market cap JPY 6,581,849,280.00, and cash per share JPY 90.49. These figures imply solid balance-sheet cushioning but high valuation multiple vs minimal revenue, consistent with a development-stage biotech.

Outlook, Meyka AI forecast and short-term price targets for 4893.T stock

Meyka AI’s forecast model projects monthly JPY 140.72, quarterly JPY 112.13, and yearly JPY 55.27 targets. Compared with the current price JPY 152.00, the implied changes are: monthly -7.42%, quarterly -26.22%, and yearly -63.67%. Forecasts are model-based projections and not guarantees.

For traders we set pragmatic targets: short-term support JPY 140.72, tactical stop under JPY 150.00, and a conservative recovery target near the 200-day average JPY 164.12 if positive clinical or corporate news appears. Use tight risk controls given biotech volatility.

Risks, catalysts and what to watch next for 4893.T stock

Primary risks include clinical trial setbacks, funding dilution, and continued negative EPS. Noile-Immune has no debt but very high operating losses, seen in operating margin -164.15%, which increases sensitivity to capital markets.

Catalysts: upcoming earnings/updates (next scheduled announcement 19 May 2026), clinical progress, licensing news, or partnerships could reverse sentiment. Monitor volume spikes, insider activity, and sector flows in Healthcare on the JPX.

Final Thoughts

4893.T stock is a clear intraday top loser after a 16.02% decline to JPY 152.00 on heavy 2,851,100.00 volume on the JPX. Fundamentals show deep operating losses (EPS -16.00) but strong cash per share (JPY 90.49) and a price-to-book of 1.67, making this a balance between capital risk and asset backing. Meyka AI rates 4893.T with a score of 64.82/100 (Grade B, HOLD), reflecting mixed fundamentals and sector comparisons. Meyka AI’s forecast model projects monthly JPY 140.72 (implied -7.42% vs current), quarterly JPY 112.13 (implied -26.22%), and yearly JPY 55.27 (implied -63.67%); forecasts are model-based projections and not guarantees. Traders should treat moves as high-volatility opportunities and prioritize tight stops or hedging. For longer-term investors, watch the May 2026 earnings window, clinical updates, and cash-burn disclosure. For more real-time signals and grading, use our Meyka AI-powered market analysis platform and the company site for corporate releases Noile-Immune Biotech and the company profile image profile.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.